Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03836209
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
- NCT03836209 ↗
- Completed
- PrECOG, LLC.
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| X threads | 5 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Gilteritinib; Midostaurin; Daunorubicin; Cytarabine
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 181
- Primary outcomes
- FLT3 Mutation Negative Composite Complete Response (CRc) [Includes Complete Response (CR) or CR With Incomplete Hematologic Recovery (CRi)] at End of Induction
- Sponsor
- PrECOG, LLC. with Astellas Pharma Inc
- Start
- Dec 6, 2019
- Primary completion
- Oct 17, 2023
- Results posted
- Yes
- Registry record
- NCT03836209 · updated Jul 23, 2026